Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Essential Pharma will leverage Renaissance clinical-stage immunotherapy product Hu14.18 (Hu14.18K322A) for the treatment of high-risk neuroblastoma.
Lead Product(s): Hu14.18K322A
Therapeutic Area: Oncology Product Name: Hu14.18
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 09, 2024
Details:
Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Product Name: Hu14.18K322A
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: St. Jude Children’s Research Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023